Education
About Us
Working with TipRanks
Follow Us
AbCellera Biologics (ABCL)
NASDAQ:ABCL
ABCL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.89 - $5.82
Previous CloseN/A
Volume1.71M
Average Volume (3M)6.60M
Market Cap
$1.37B
Enterprise Value$587.89M
Total Cash (Recent Filing)$605.27M
Total Debt (Recent Filing)$67.85M
Price to Earnings (P/E)―
Beta1.47
Next Earnings
Nov 11, 2025EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding298,832,920
10 Day Avg. Volume6,208,938
30 Day Avg. Volume6,595,994
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.43
Enterprise Value/Revenue25.43
Enterprise Value/Gross Profit-5.36
Enterprise Value/Ebitda-2.89
Forecast
1Y Price Target
$8.42Price Target Upside83.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Bulls Say, Bears Say
Bulls Say
Financial PerformanceAbCellera Biologics reported a significant increase in revenues for the second quarter, reaching $17.1 million compared to $7.3 million in the prior year period, supported by a Trianni-license backed milestone payment.
Market OpportunitiesABCL575 and ABCL635 are set to enter Phase 1 trials, targeting large commercial opportunities with promising data expected in the future.
Pipeline DevelopmentAbCellera's initiation of dosing for its clinical asset, ABCL-575, for moderate-to-severe vasomotor symptoms marks an important milestone in its transition towards a biotech identity.
Bears Say
Analyst RatingAnalyst is maintaining a Hold rating on ABCL shares as the Company decreases its revenue-generating development partnership activities and focuses more on its internal pipeline development.
Clinical RiskThere is a clinical risk for targeting NK3R with ABCL635 due to concerns about sufficient target engagement and potential safety issues related to liver toxicity.
Revenue GenerationThe Company is decreasing its revenue-generating development partnership activities and focusing more on its internal pipeline development.
AbCellera Biologics News
ABCL FAQ
What was AbCellera Biologics’s price range in the past 12 months?
AbCellera Biologics lowest stock price was $1.89 and its highest was $5.82 in the past 12 months.
What is AbCellera Biologics’s market cap?
AbCellera Biologics’s market cap is $1.37B.
When is AbCellera Biologics’s upcoming earnings report date?
AbCellera Biologics’s upcoming earnings report date is Nov 11, 2025 which is in 85 days.
How were AbCellera Biologics’s earnings last quarter?
AbCellera Biologics released its earnings results on Aug 07, 2025. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.134 by $0.014.
Is AbCellera Biologics overvalued?
According to Wall Street analysts AbCellera Biologics’s price is currently Undervalued.
Does AbCellera Biologics pay dividends?
AbCellera Biologics does not currently pay dividends.
What is AbCellera Biologics’s EPS estimate?
AbCellera Biologics’s EPS estimate is -0.14.
How many shares outstanding does AbCellera Biologics have?
AbCellera Biologics has 298,832,920 shares outstanding.
What happened to AbCellera Biologics’s price movement after its last earnings report?
AbCellera Biologics reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.134. Following the earnings report the stock price went up 0.236%.
Which hedge fund is a major shareholder of AbCellera Biologics?
Currently, no hedge funds are holding shares in ABCL
AbCellera Biologics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.42 (83.44% Upside)
$8.42 (83.44% Upside)
Blogger Sentiment
Neutral
ABCL Sentiment 50%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 544.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.8%
Last 30 Days ▲ 20.9%
Last 30 Days ▲ 20.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
75.19%
12-Months-Change
Fundamentals
Return on Equity
-15.64%
Trailing 12-Months
Asset Growth
-0.74%
Trailing 12-Months
Company Description
AbCellera Biologics
AbCellera Biologics Inc. is a biotechnology company specializing in the discovery and development of therapeutic antibodies. Operating within the biopharmaceutical sector, the company leverages its advanced proprietary technology platforms to rapidly identify and develop antibody therapies. AbCellera partners with pharmaceutical companies to enhance the drug discovery process, focusing on accelerating the path from target to lead candidate.
ABCL Company Deck
ABCL Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant advancements in clinical trials and a strong financial position, with increased revenue and pipeline development. However, it also included a reported net loss and anticipated decline in research fee revenue.View all ABCL earnings summariesABCL Revenue Breakdown
93.51% Research fees
3.94% Royalty revenue
2.55% Milestone payments
ABCL Stock 12 Month Forecast
Average Price Target
$8.42
▲(83.44% Upside)
Technical Analysis
Gyre Therapeutics
―
Xeris Pharmaceuticals
―
CureVac
―
Praxis Precision Medicines
―
Pharvaris
―
Ownership Overview
38.43% Insiders
4.85% Mutual Funds
22.38% Other Institutional Investors
33.06% Public Companies and Individual Investors